Semorinemab (RG 6100), an anti-Tau humanized IgG4 monoclonal antibody, selectively targets the N-terminal portion of the Tau protein, specifically amino acid residues 6-23. It exhibits a binding affinity to human Tau with a dissociation constant (Kd) of 3.8 nM. This compound is utilized in Alzheimer's Disease research [1].